Abeona Therapeutics (NASDAQ:ABEO) Issues Earnings Results

Abeona Therapeutics (NASDAQ:ABEO) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.12), FiscalAI reports. The business had revenue of $11.38 million for the quarter, compared to analyst estimates of $12.24 million.

Here are the key takeaways from Abeona Therapeutics’ conference call:

• ZEVASKYN revenue rose 31% quarter over quarter to $11.4 million, with four revenue-generating treatments recognized in the second quarter. Abeona ended June with $146.8 million in cash, cash equivalents, and short-term investments.
• The commercial rollout expanded to seven activated qualified treatment centers, and 12 patients have been treated since launch, including five in Q2 and three more in Q3 to date. The company estimates about 40% of its addressable market now has in-state access to a treatment center.
• Launch execution remains operationally complex, with scheduling disruptions, two last-minute biopsy cancellations, one low-yield batch, and one out-of-specification batch. Both affected patients were treated, but Abeona will recognize no revenue for those two treatments and said the long-term rate of non-billable units remains uncertain.
• CMS granted ZEVASKYN New Technology Add-on Payment status effective October 1, 2026, making it one of only three of 15 traditional-pathway applicants to receive the designation. Although Medicare represents roughly 10% of the payer mix, Abeona expects NTAP to improve hospital economics and potentially support broader payer negotiations.
• Abeona reported a second-quarter net loss of $20.2 million, or $0.35 per share, compared with a $17.1 million loss in Q1. Gross margin was approximately 63%, though management expects margins could reach 85%–90% at steady-state volume as fixed manufacturing costs are spread across more treatments.

Abeona Therapeutics Stock Down 4.1%

Abeona Therapeutics stock opened at $6.08 on Friday. Abeona Therapeutics has a 12 month low of $4.00 and a 12 month high of $7.65. The stock has a fifty day simple moving average of $6.30 and a two-hundred day simple moving average of $5.57. The company has a current ratio of 5.89, a quick ratio of 5.70 and a debt-to-equity ratio of 0.03. The firm has a market cap of $346.50 million, a price-to-earnings ratio of 6.19 and a beta of 1.35.

Insiders Place Their Bets

In other news, insider Madhav Vasanthavada sold 12,606 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $6.96, for a total transaction of $87,737.76. Following the transaction, the insider directly owned 290,623 shares of the company’s stock, valued at $2,022,736.08. This represents a 4.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Brendan M. O’malley sold 12,050 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $6.96, for a total value of $83,868.00. Following the completion of the transaction, the senior vice president directly owned 427,953 shares in the company, valued at approximately $2,978,552.88. This represents a 2.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 281,078 shares of company stock worth $1,709,923 in the last quarter. Insiders own 7.10% of the company’s stock.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ABEO. Deutsche Bank AG raised its position in shares of Abeona Therapeutics by 6.2% during the fourth quarter. Deutsche Bank AG now owns 39,368 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 2,303 shares during the last quarter. LPL Financial LLC grew its holdings in shares of Abeona Therapeutics by 5.3% in the fourth quarter. LPL Financial LLC now owns 62,873 shares of the biopharmaceutical company’s stock valued at $331,000 after purchasing an additional 3,165 shares in the last quarter. Intech Investment Management LLC lifted its position in Abeona Therapeutics by 19.6% during the third quarter. Intech Investment Management LLC now owns 25,176 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 4,127 shares during the last quarter. Creative Planning grew its position in Abeona Therapeutics by 43.0% in the second quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 4,305 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in Abeona Therapeutics during the second quarter worth approximately $27,000. 80.56% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ABEO. Wall Street Zen upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Weiss Ratings lowered shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, August 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research note on Thursday, May 28th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $19.00.

About Abeona Therapeutics

Abeona Therapeutics is a clinical?stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life?threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non?viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV?based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.